Studios

Four governed Studios for biopharma decisions.

ARiDA is one invite-only decision-intelligence platform. Its Studios are the focused product modules for valuation, indication strategy, portfolio decisions, and evidence-only patent intelligence.

Book a Demo

Asset and portfolio value

Valuation Studio

Build defensible asset, portfolio, and board valuation outputs with source-bound assumptions, rNPV, Monte Carlo risk, real options, value of information, and scenario analysis.

Built for source-bound rNPV, Monte Carlo risk, real options, value of information, and board-ready assumption review.

Inputs

Asset or portfolio description
Development stage and indication context
Clinical, regulatory, market, and IP evidence
User assumptions for costs, timing, PoS, pricing, and scenarios

Outputs

Risk-adjusted valuation summary
Monte Carlo distribution and downside views
Real-options and VOI analysis
Assumption register and board-ready narrative

Expansion strategy

Indication Studio

Rank and sequence where a mechanism, asset, or platform should go next by combining biology, clinical feasibility, market structure, competitive pressure, IP context, and valuation logic.

Inputs

Asset, target, mechanism, or platform description
Current or excluded indications
Decision context and weighting preferences
Clinical, literature, target, market, regulatory, and IP evidence

Outputs

Ranked indication shortlist
Biology and feasibility evidence matrix
Attractiveness and value cockpit
Expansion sequence and decision brief

Capital allocation

Portfolio Studio

Prioritize programs, capital, and strategic tradeoffs across assets or targets with MCDA, portfolio valuation, scenario stress tests, allocation views, and source-bound decision outputs.

Inputs

Asset, target, or program universe
Budget, timing, and portfolio constraints
Criteria weights and risk appetite
Evidence and assumptions from internal files or public sources

Outputs

Prioritized asset or target scorecard
Portfolio allocation and efficient-frontier views
Scenario and stress-test outputs
Decision brief with assumption provenance

Evidence-only IP intelligence

Patent Studio

Map patent families, assignees, claim themes, exclusivity context, LOE signals, and evidence-only IP strategy questions without presenting legal opinions or clearance conclusions.

Built to keep legal advice, clearance opinions, and unsupported claims out of scope while you inspect patent-family evidence.

Inputs

Technology, product, target, or competitor scope
Jurisdictions and date windows
Assignee, patent-family, product, or modality context
Patent, regulatory, litigation, and commercial evidence

Outputs

Patent-family and assignee landscape
Claim-context and evidence tables
LOE and exclusivity intelligence
Evidence-indexed IP strategy brief

Comparison

Choose the Studio by the decision you need to defend.

Studio	Decision	Primary inputs	Primary outputs	Best for
Valuation Studio	What is the defensible value range for this asset or portfolio?	Asset or portfolio description; Development stage and indication context	Risk-adjusted valuation summary; Monte Carlo distribution and downside views	Biotech founders, CFOs, pharma BD teams, investors, portfolio leaders, and valuation advisors.
Indication Studio	Which indications should enter the shortlist and why?	Asset, target, mechanism, or platform description; Current or excluded indications	Ranked indication shortlist; Biology and feasibility evidence matrix	R&D strategy teams, platform biotech leaders, translational teams, investors, and BD groups.
Portfolio Studio	Which assets or targets should receive capital first?	Asset, target, or program universe; Budget, timing, and portfolio constraints	Prioritized asset or target scorecard; Portfolio allocation and efficient-frontier views	Portfolio committees, biotech leadership teams, investors, strategy teams, and pharma BD groups.
Patent Studio	What patent families, assignees, and claim themes shape the strategic landscape?	Technology, product, target, or competitor scope; Jurisdictions and date windows	Patent-family and assignee landscape; Claim-context and evidence tables	Biotech leadership, IP strategy teams, patent counsel partners, BD teams, investors, and diligence teams.

Private beta

See which Studio fits your next decision.

Book a Demo